Not Yet Recruiting
The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors
NCT06772610
- Conditions
- ALK, Adjuvant Treatment, NSCLC, +1 more
- Locations
-
Not specified